|Molar mass||418.33 g/mol|
Except where noted otherwise, data is given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
|what is: / ?)(|
Chromium (III) picolinate (CrPic3) is a chemical compound sold as a nutritional supplement to prevent or treat chromium deficiency. This bright-red coordination compound is derived from chromium (III) and picolinic acid. Small quantities of chromium are needed for glucose utilization by insulin in normal health, but deficiency is extremely rare and has only been observed in hospital patients on long-term defined diets. Chromium has been identified to regulate insulin by increasing the sensitivity of the insulin receptor. As such, chromium (III) picolinate has been used as a treatment for type 2 diabetes, although its effectiveness remains controversial due to conflicting and/or poorly carried out clinical studies. Chromium (III) picolinate has been described as a "poor [...] nutritional supplement".
- 1 History
- 2 Physical Properties
- 3 Biochemistry of Chromium (III) Picolinate
- 4 Mechanism of action
- 5 Health Claims and debates
- 6 Safety and Toxicity
- 7 Regulation of chromium III picolinate
- 8 References
- 9 External links
A study in 1989 suggested that chromium (III) picolinate may assist in weight loss and increase muscle mass which led to an increase in the usage of chromium (III) picolinate supplements, making it the second most widely used supplement behind Ca2+ supplements. This claim has been disproven by a Cochrane review in 2013. Research has generally shown that it improves insulin sensitivity by either prolonging its activity or up-regulating the production of mRNA to produce more insulin receptors.
Amongst the transition metals, Cr3+ is the most controversial in terms of nutritional value and toxicity. This controversy centers on whether Cr3+ provides any nutritional benefits given that Cr3+ nutritional supplements for humans form the basis of a multimillion dollar industry with sales second behind Ca-containing products. Furthermore, this controversy is amplified by the fact that no Cr-containing biomolecules have had their structure characterized, nor has the mode of action been determined. The first experiment that led to the discovery of Cr3+ playing a role in glucose metabolism proposed that the biologically active form of the metal existed in a protein called “glucose tolerance factor”, however, new evidence suggests that it is simply an artifact obtained from isolation procedures. The only accepted indicator of chromium deficiency is the reversal of symptoms that occurs when chromium (III) supplementation is adminstered to hospital patients that were on total parenteral nutrition (which lacked chromium (III)) for an extensive period of time. 
Chromium (III) picolinate is a pinkish-red compound and was first reported in 1917. It is poorly soluble in water, having a solubility of 600 µM in water at near neutral pH. At lower pH levels, the complex hydrolyzes to release picolinic acid and free Cr3+.
Biochemistry of Chromium (III) Picolinate
Chromium has been identified as an essential nutrient in maintaining normal blood glucose levels and as such, it is proposed to interact with two naturally occurring molecules found within the body.
Low-Molecular-Weight Chromium-Binding Substance (LMWCr)
Low molecular weight chromium binding substance, also known as chromodulin, is a naturally occurring oligopeptide that has been found to bind to chromium since its first isolation by Wada et al. in 1981. Chromodulin is known to act on insulin receptors by prolonging kinase activity through stimulating the tyrosine kinase pathway, thus leading to improved glucose absorption. The exact mechanisms underlying this process are currently unknown. Evidence for the existence of this protein comes from the fact that the removal of 51Cr in the blood exceeds the rate of 51Cr formation in the urine. This indicates that the transport of Cr3+ must involve an intermediate (i.e. chromodulin) and that Cr3+ is moved from the blood to tissues in response to increased levels of insulin. Subsequent protein isolations in rats, dogs, mice and cows have shown the presence of a similar substance, suggesting that it is found extensively in mammals. This oligopeptide is small, having a molecular weight of around 1 500 g/mol and the predominant amino acids present are glutamic acid, glycine, and cysteine. Despite recent efforts to characterize the exact structure of chromodulin, it is still relatively unknown.
Nature of Chromodulin Binding
From spectroscopic data, it has been shown that Cr3+ binds tightly to chromodulin (Kf = 1021 M−4), and that the binding is highly cooperative (Hill Coefficient = 3.47). It has been shown that holochromodulin binds 4 equivalents of Cr3+. Evidence for this comes from in vitro studies which showed that apochromodulin exerts its maximal activity on insulin receptors when titrated with 4 equivalents of Cr3+. Chromodulin is highly specific for Cr3+ as no other metals are able to stimulate tyrosine kinase activity. It is believed to stimulate the phosphorylation of the 3 tyrosine residues of the β subunits of the insulin receptor. From electronic studies, the crystal field stabilization energy was determined to be 1.74 x 103 while the Racah parameter B was 847 cm−1. This indicates that chromium binds to chromodulin in the trivalent form. In addition, magnetic susceptibility studies have shown that chromium does not coordinate to any N-terminal amine groups but rather to carboxylates (although the exact the amino acids involved are still unknown). These magnetic susceptibility studies are consistent with the presence of a mononuclear Cr3+ center and an unsymmetric trinuclear Cr3+ assembly with bridging oxo ligands. In chromodulin isolated from bovine liver, x-ray absorption spectroscopy studies have shown that the chromium (III) atoms are surrounded by 6 oxygen atoms with an average Cr—O distance of 1.98 Å, while the distance between 2 chromium (III) atoms is 2.79 Å. These results are indicative of a multinuclear assembly. No sulfur ligands coordinate to chromium and instead, it has been proposed that a disulfide linkage between 2 cysteine residues occurs owing to a characteristic peak at 260 nm.
Absorption and Excretion of Chromium (III) Picolinate
Once chromium (III) picolinate is ingested and enters the stomach, acidic hydrolysis of the complex occurs when in contact with the stomach mucosa. The hydrolyzed Cr3+ is present in the hexaaqua form and polymerizes to form an insoluble Cr(III)-hydroxide-oxide (the process of olation) once it reaches the alkaline pH of the small intestine. Approximately 2 % of Cr3+ is absorbed through the gut as chromium (III) picolinate via unsaturated passive transport. Although absorption is low, organic sources of Cr3+ such as CrPic3 absorb more efficiently than inorganic sources (i.e. CrCl3) and thus accumulate at higher concentrations in tissues. This has been one major selling point for chromium (III) picolinate over other chromium (III) supplements. Organic sources tend to absorb better as they have ligands which are more lipophilic and usually neutralize the charge of the metal, thus permitting for easier passage through the intestinal membrane.
It has also been shown that dietary factors have an impact on Cr3+ absorption. Starch, simple sugars, oxalic acid, and some amino acids tend to increase the rate of absorption of chromium (III). This is a result of ligand chelation, converting hexaaqua Cr3+ into more lipophilic forms. In contrast, calcium, magnesium, titanium, zinc, vanadium, and iron reduce the rate of absorption. Presumably, these ions introduce new metal-ligand equilibria, thus decreasing the lipophilic ligand pool available to Cr3+. Once absorbed into the bloodstream, 80% of the Cr3+ from CrPic3 is passed along to transferrin. The exact mechanism of release is currently unknown, however, it is believed not to occur by a single electron reduction, as in the case of Fe3+, due to the high instability of Cr2+. Administered Cr3+ can be found in all tissues ranging from 10-100 μg/kg body weight. It is excreted primarily in the urine (80 %) while the rest is excreted in sweat and feces.
Binding of Chromium (III) to Transferrin
Transferrin, in addition to chromodulin has been identified as a major physiological chromium transport agent. While transferrin is highly specific for ferric ions, at normal conditions, only 30% of transferrin molecules are saturated with ferric ions, allowing for other metals, particularly those with a large charge to size ratio, to bind as well. The binding sites consist of a C-lobe and an N-lobe which are nearly identical in structure. Each lobe contains aspartic acid, histidine, 2 tyrosine residues and a bicarbonate ion that acts as a bidentate ligand to allow iron or other metals to bind to transferrin in a distorted octahedral geometry. Evidence supporting the binding of Cr3+ to transferrin comes from extensive clinical studies that showed a positive correlation between levels of ferritin and of fasting glucose, insulin, and glycosylated hemoglobin (Hb1Ac) levels. Furthermore, an in vivo study in rats showed that 80 % of isotopically labelled Cr3+ ended up on transferrin while the rest were bound to albumin. An in vitro study showed that when chromium (III) chloride was added to isolated transferrin, the Cr3+ readily bound transferrin, owing to changes in the UV-Vis spectrum. The formation constant for Cr3+ in the C-lobe is 1.41 x 1010 M−1 and 2.04 x 105 M−1 in the N-lobe, which indicates that Cr3+ preferentially binds the C-lobe. Overall, the formation constant for chromium (III) is lower than that of the ferric ion. The bicarbonate ligand is crucial in binding Cr3+ as when bicarbonate concentrations are very low, the binding affinity is also significantly lower. Electron paramagnetic resonance (EPR) studies have shown that below pH 6, chromium (III) binds only to the N-lobe and that at near neutral pH, chromium (III) binds to the C-lobe as well.  Chromium (III) can compete with the ferric ion for binding to the C-lobe when the saturation greatly exceeds 30 %. As such, these effects are only seen in patients suffering from hemochromatosis, an iron-storage disease characterized by excessive iron saturation in transferrin.
Mechanism of action
Although chromodulin's exact mechanism of action on the insulin receptor is currently unknown, one commonly described mechanism is presented below. This proposed mechanism has the highest amount of agreement with various experiments involving chromodulin.
Normally, chromodulin exists in the apochromodulin form, which is free of Cr (III) ions and has minimal activity on insulin receptors. The apochromodulin is stored in insulin sensitive cells in the nucleus. When blood glucose levels rise, insulin is released into the bloodstream and binds to an external α-subunit of the insulin receptor, a transmembrane protein. The insulin receptor consists of 2 extracellular α-subunits and 2 transmembrane β-subunits. As soon as insulin binds to the insulin receptor, a conformational change in the receptor occurs, causing all 3 tyrosine residues (located in the β-subunits) to be phosphorylated. This activates the receptor and allows it to transmit the signal from insulin to the cell. As mentioned above, absorbed chromium (III) picolinate eventually gives up Cr3+ to transferrin. In turn, transferrin transports Cr3+ to insulin sensitive cells (i.e. adipocytes) where it binds to apochromodulin to form holochromodulin. Holochromodulin binds to the insulin receptor, which assists in maintaining the active conformation of the insulin receptor by prolonging the kinase activity of several kinases or up-regulating the amount of insulin receptor mRNA levels, thus decreasing blood glucose levels.
Another way that Cr(III) may prolong the receptor's kinase activity is through the oxidation of a critical active site cysteine residue on protein-tyrosine phosphatase 1B (PTP1B). Normally, PTP1B dephosphorylates phosphotyrosine residues by carrying out nucleophilic attack on the phosphate group via its cysteine residue, thus inactivating the insulin receptor. This process removes the phosphate group from the tyrosine residue to form a Cys—S—PO32- group that is subsequently hydrolyzed by water to regenerate the cysteine residue, permitting for another round of action. Research has shown that chromium (III) may in fact cause irreversible inhibition of PTP1B. It is thought that Cr(III) is converted to Cr(VI) or Cr(V) (through the action of oxidoreductases) which then oxidize the thiol of the cysteine residue on PTP1B to sulfenic acid, consequently rendering it unable to attack the phosphate group on phosphotyrosine. However, this is only a plausible mechanism, and no direct evidence has been shown to support this hypothesis.
When the signal cascade is turned off, holochromodulin is eliminated in urine since the formation constant is too large to remove Cr(III) directly. Experimental evidence has shown that the loss of chromodulin from cells is correlated with an increase in chromium concentrations in the urine after ingesting food rich in carbohydrates (i.e. glucose).
Health Claims and debates
Some commercial organizations promote chromium picolinate as an aid to body development for athletes and as a means of losing weight. But a number of studies have failed to demonstrate an effect of chromium picolinate on either muscle growth or fat loss. In general, there is no good evidence that chromium picolinate supplementation helps people lose weight.
Treatment of Diabetes Mellitus Type 2
There are claims that the picolinate form of chromium supplementation aids in reducing insulin resistance, particularly in diabetics(type 2), but a meta-analysis of chromium (III) supplementation studies showed no association between chromium and glucose or insulin concentrations for non-diabetics, and inconclusive results for diabetics. This study has been challenged on the grounds that it excluded significant results. Subsequent trials gave mixed results, with one finding no effect in people with impaired glucose tolerance, but another seeing a small improvement in glucose resistance. A further study on obese adults with metabolic syndrome was published in 2009, this found no significant effect on insulin sensitivity, but increased short-term levels of insulin. The study also observed no effect on body weight or serum lipid levels.
In a review of these trials it was again concluded that chromium supplements had no effect on healthy people, but that there might be an improvement in glucose metabolism in diabetics, although the authors stated that the evidence for this effect remains weak. Although the authors of this study mentioned that chromium (III) picolinate decreases HbA1c levels (measure of plasma glucose concentration) by 0.7% (95% CI) in type 2 diabetes patients, they noted that most poor quality studies produced larger positive outcomes than higher quality studies. It has also been shown that the supplement does not alter blood glucose levels in non-diabetics. In addition, the effects exhibited by Cr(III) species have long term effects on the blood glucose levels of diabetes patients. In comparison to chromium chloride, chromium picolinate is more effective at lowering blood glucose levels. Chromium chloride lowers blood glucose levels by 0.3 mM whereas chromium picolinate lowers blood glucose levels by 0.8 mM. However, opinions differ on this conclusion - a review published in 2006 argued that these data instead supported the clinical efficacy of chromium picolinate for the treatment of type 2 diabetes. In 2006, the U.S. Food and Drug Administration stated that the "relationship between chromium picolinate intake and insulin resistance is highly uncertain".
Variability of studies
There was no consistency observed in clinical results relating chromium picolinate to adequate treatment of type 2 diabetes. This is due to the degree of glucose intolerance of patients that participate in the clinical studies. Glucose intolerance is a gradient and the intensity is affected by ethnicity, degree of obesity, age, distribution of body fat and many other factors. In some studies, low dosages of the supplement were given, however, a suitable amount of chromium picolinate must be administrated to a person before any appreciable drop in glucose levels are observed due to differing levels of insulin resistance. Another important point to mention is that diabetes is not always caused by glucose intolerance.  As mentioned before, Cr(III) has been shown to only influence glucose intolerance and not insulin levels. Furthermore, the environments in which the studies were performed were not consistent. The levels of stress, diets consumed by patients and patient genetics were variable among study subjects. Also, as mentioned in the absorption and excretion section, the absorption/bioavailability of chromium picolinate is influenced by the diet. Collectively, these different factors have contributed to the variability in the studies.
Compared to the most widely and longest used type 2 diabetes treatment, metformin, chromium picolinate is less effective at lower blood glucose levels over a long term. Metformin targets an insulin independent AMPK pathway within liver cells to reduce the circulation of glucose within the bloodstream with very minimal side effects. Compared to Cr (III) species, metformin performs both more consistently and effectively, lowering HbA1c by 1.12 %, compared to 0.6 % with chromium picolinate (although data for it is weak). Thus, in comparison to the leading type II diabetes treatment, chromium (III) picolinate does not serve as an appropriate treatment for the disease.
Safety and Toxicity
Initial concerns were raised that chromium picolinate is more likely to cause DNA damage and mutation than other forms of trivalent chromium, but these results are also debated. These concerns were based, in part, on studies in fruit flies, where chromium(III) picolinate supplementation generates chromosomal aberrations, impedes progeny development, and causes sterility and lethal mutations.
Though chromium (III) picolinate has been used as a supplement for decades, toxicity concerns did not begin to arise until the late 1990s. By that time, it was established that other oxidation states of chromium – mainly chromium (VI) – were in fact toxic to human health and acted as carcinogens through clastogenic effects. It was found that when chromium (IV) complexes were under physiological conditions they were reduced by vitamin C and glutathione to form reactive intermediate complexes. Though direct evidence has not been obtained, it is hypothesized that chromium (IV) metabolism involves the formation of a reactive Cr (V) species, which causes DNA damage before going to the Cr(III) oxidation state. From all the studies conducted on Cr(VI), researchers wanted to see if the toxicity of Cr(III) could be as concerning, especially since studies showing chromium picolinate (CrPic3) could oxidize DNA in vitro began to emerge.
In 1995 researchers conducted an in vitro study on the toxic effects of Cr (III) picolinate on Chinese hamster ovary cells. The results showed that at concentrations of 0.050—1.0 mM, chromium (III) picolinate caused chromosomal damage. This toxicity was linked to the role of CrPic3 as a mutagen in the cells, resulting in mitochondrial damage and apoptosis. However a similar study on the same types of ovary cells showed contradictory results i.e. cell toxicity. This discrepancy was solved by analyzing the experimental conditions more closely. It was found that the former study was done dissolving CrPic3 in acetone, and the latter in DMSO. DMSO acts as a radical scavenger, potentially removing any reactive oxygen species and preventing toxicity. Since then, many studies done on mammalian cells have shown that CrPic3 is indeed toxic, and most likely exerts its effect through generation of radical species which results in DNA damage. This hypothesis has been supported my numerous studies in which CrPic3 was administered in both radical scavenging solvents (methanol, DMSO) and normal solvents (acetone, water). Results consistently show that toxicity effects were only averted in radical scavenging solvents. Unlike the Cr(VI) complexes however, it was thought that these carcinogenic effects were due to picolinic acid itself, and not the metal ion.
Shortly thereafter, another study was published to assess the toxicity of Cr(III) picolinate, this time on humans. The researchers that conducted this study used previous knowledge that Cr(III) is reduced to Cr(II) by cellular reductants such as NADH or cysteine. This reduced form of Cr(II) is shown to react with H2O2 to generate radical species which in turn oxidize DNA base pairs. With this knowledge in mind, the researchers administered ten women with 400 μm of chromium (III) picolinate a day for a eight week period. By measuring the amount of an oxidized DNA base pair, 5-hydroxymethyl uracil using antibody titers, the group could infer the amount of DNA base pair oxidation occurring in direct relation to chromium (III) picolinate. The results of the study suggested that chromium (III) picolinate itself does not cause significant chromosomal damage in vivo.
Generally speaking, it has been shown that chromium (III) picolinate is not toxic to humans. As a matter of fact, to see the same toxicity effects as seen with Cr(VI) compounds, the user would need to ingest orders of magnitude higher concentrations of Cr(III). For most adults, chromium (III) picolinate can be taken orally in doses up 1000 mg per day. This low toxicity has general been associated with low absorbance of Cr(III) in the body through the lungs, skin and gastrointestinal tract, coupled with high excretion. Normally, 99% of chromium (III) taken can be recovered in the feces of the user. On the contrary, there have been isolated incidences of chromium (III) supplementation leading to kidney failure, however this relationship is unclear and has yet to remain tested.
Based on empirical data then, it can be said that chromium picolinate is a safe, non-toxic supplement for Cr(III). Thus, whether or not chromium picolinate aids diabetic patients, the fact of the matter is that users are not at risk from chromium picolinate toxicity.
Regulation of chromium III picolinate
In 2004, the UK Food Standards Agency advised consumers to use other forms of trivalent chromium in preference to chromium picolinate until specialist advice was received from the Committee on Mutagenicity. This was due to concerns raised by the Expert Group on Vitamins and Minerals that chromium picolinate might cause cancer (its genotoxicity). The committee also noted two case reports of renal failure that might have been caused by this supplement and called for further research into its safety. In December 2004, the Committee on Mutagenicity published its findings, which concluded that "overall it can be concluded that the balance of the data suggest that chromium picolinate should be regarded as not being mutagenic in vitro" and that "the available in-vivo tests in mammals with chromium picolinate are negative.". Following these findings, the UK Food Standards Agency withdrew its advice to avoid chromium picolinate, though it plans to keep its advice about chromium supplements under review.
In 2010, chromium picolinate was approved by Health Canada to be used in dietary supplements. The monograph includes use in capsules, chewables (e.g. gummies, tablets), liquids, powders, strips or tablets. Approved labeling statements include: a factor in the maintenance of good health, provides support for healthy glucose metabolism, helps the body to metabolize carbohydrates and helps the body to metabolize fats.
- Preuss, H. G.; Echard, B.; Perricone, N. V.; Bagchi, D.; Yasmin, T.; Stohs, S. J. (2008). "Comparing metabolic effects of six different commercial trivalent chromium compounds". Journal of Inorganic Biochemistry 102 (11): 1986–1990. doi:10.1016/j.jinorgbio.2008.07.012. PMID 18774175.
- Review of Chromium Expert Group on Vitamins and Minerals Review of Chromium, 12 August 2002
- Stearns DM (2000). "Is chromium a trace essential metal?". BioFactors 11 (3): 149–62. doi:10.1002/biof.5520110301. PMID 10875302.
- Vincent, John (2010). "Chromium: celebrating 50 years as an essential element?". Dalton Transactions (Royal Society of Chemistry) 39: 3787–3794. doi:10.1039/B920480F. Retrieved 20 March 2015.
- Tian, H; Guo, X; Wang, X; He, Z; Sun, R; Ge, S; Zhang, Z (2013). "Chromium picolinate supplementation for overweight or obese adults". The Cochrane database of systematic reviews 11. doi:10.1002/14651858.CD010063.pub2. PMID 24293292. CD010063.
- Levina, Aviva; Lay, Peter (2008). "Chemical Properties and Toxcity of Chromium (III) Nutritional Supplements". Chemical Research in Toxicology (American Chemical Society) 21 (3): 563–571. doi:10.1021/tx700385t. Retrieved 20 March 2015.
- Feng, Weiyue (2007). "Chapter 6—The Transport of chromium (III) in the body: Implications for Function". In Vincent, John. The Nutritional Biochemistry of Chromium (III). Amsterdam: Elsevier B.V. pp. 121–137. ISBN 978-0-444-53071-4. Retrieved 20 March 2015.
- Cefalu, William; Hu, Frank (2004). "Role of Chromium in Human Health and in Diabetes". Diabetes Care (American Diabetes Association) 27 (11): 2741–2751. doi:10.2337/diacare.27.11.2741. Retrieved 20 March 2015.
- Anderson, Richard (1998). "Chromium, Glucose Intolerance and Diabetes". Journal of the American College of Nutrition (American College of Nutrition) 17 (6): 548–555. doi:10.1080/07315724.1998.10718802. Retrieved 20 March 2015.
- Vincent, John (2004). "Recent advances in the nutritional biochemistry of trivalent chromium". Proceedings of the Nutrition Society (Cambridge University Press) 63 (1): 41–47. doi:10.1079/PNS2003315. Retrieved 20 March 2015.
- Vincent, John (2001). "The Bioinorganic Chemistry of Chromium (III)". Polyhedron (Elsevier B.V) 20: 1–26. Retrieved 20 March 2015.
- Vincent, John (2000). "The Biochemistry of Chromium". The Journal of Nutrition (American Society for Nutrition) 130 (4): 715–718. Retrieved 20 March 2015.
- Vincent, John (2015). "Is the Pharmacological Mode of Action of Chromium (III) as a secondary messenger?". Biological Trace Element Research (Springer). doi:10.1007/s12011-015-0231-9. Retrieved 20 March 2015.
- Vincent, John (2012). "The binding and transport of alternative metals by transferrin". Biochimica et Biophysica Acta (BBA)—General Subjects (Elsevier B.V) 1820 (3): 362–378. Retrieved 20 March 2015.
- Vincent, John (2012). "Biochemical Mechanisms". In Vincent, John. The Bioinorganic Chemistry of Chromium. Chichester, UK: John Wiley & Sons. pp. 125–167. doi:10.1002/9781118458891.ch6. ISBN 9780470664827. Retrieved 20 March 2015.
- Lukaski, Henry (2007). "Chapter 4—Effects of Chromium(III) as a nutritional supplement". In Vincent, John. The Nutritional Biochemistry of Chromium (III). Amsterdam: Elsevier B.V. pp. 57–70. ISBN 978-0-444-53071-4. Retrieved 20 March 2015.
- Laschinsky, Niels; Kottwitz, Karin; Freund, Barbara; Dresow, bernd; Fischer, Roland; Nielsen, Peter (2012). "Bioavailability of chromium(III)-supplements in rats and humans". BioMetals (Springer) 25 (5): 1051–1060. doi:10.1007/s10534-012-9571-5. Retrieved 20 March 2015.
- Debski, B.; Goniewicz, M.; Krzyzowskal, M.; Lewicka, A.; Lewickil, S.; Niemcewiz, M.; Zdanowskil, R. (2014). "The role of Chromium III in the organism and its possible use in diabetes and obesity treatment". Annals of Agricultural and Environmental Medicine 21 (2): 331–335. doi:10.5604/1232-1966.1108599.
- Quarles, C.; Marcus, R.; Brumaghim, Julia (2011). "Competitive binding of Fe3+, Cr3+, and Ni2+ to transferrin". Journal of Biological Inorganic Chemistry (Springer) 16 (6): 913–921. doi:10.1007/s00775-011-0792-9. Retrieved 20 March 2015.
- Tonks, Nicholas (2003). "PTP1B: From the sidelines to the front lines!". FEBS Letter (Elsevier B.V) 546 (1): 140–148. doi:10.1016/S0014-5793(03)00603-3. Retrieved 20 March 2015.
- Levina, Aviva (2011). "Metal based anti-diabetic drugs: advances and challenges". Dalton Transactions (Royal Society of Chemistry) 40: 11675–1686. doi:10.1039/C1DT10380F. Retrieved 28 March 2015.
- Vincent J.B.; Sack, DA; Roffman, M; Finch, M; Komorowski, JR (2003). "The potential value and toxicity of chromium picolinate as a nutritional supplement, weight loss agent and muscle development agent". Sports Medicine 33 (3): 213–230. doi:10.2165/00007256-200333030-00004. PMID 12656641.
- Pittler, M. H.; Stevinson, C; Ernst, E (2003). "Chromium picolinate for reducing body weight: Meta-analysis of randomized trials". International Journal of Obesity 27 (4): 522–9. doi:10.1038/sj.ijo.0802262. PMID 12664086.
- Tian, H; Guo, X; Wang, X; He, Z; Sun, R; Ge, S; Zhang, Z (2013). "Chromium picolinate supplementation for overweight or obese adults". The Cochrane database of systematic reviews 11. doi:10.1002/14651858.CD010063.pub2. PMID 24293292. CD010063.
- Althuis MD, Jordan NE, Ludington EA, Wittes JT (1 July 2002). "Glucose and insulin responses to dietary chromium supplements: a meta-analysis". American Journal of Clinical Nutrition 76 (1): 148–155. PMID 12081828.
- Kalman DS (1 July 2003). "Chromium picolinate and type 2 diabetes". American Journal of Clinical Nutrition 78 (1): 192; author reply 192–3. PMID 12816793.
- Gunton JE, Cheung NW, Hitchman R et al. (2005). "Chromium supplementation does not improve glucose tolerance, insulin sensitivity, or lipid profile: a randomized, placebo-controlled, double-blind trial of supplementation in subjects with impaired glucose tolerance". Diabetes Care 28 (3): 712–3. doi:10.2337/diacare.28.3.712. PMID 15735214.
- Singer GM, Geohas J (2006). "The effect of chromium picolinate and biotin supplementation on glycemic control in poorly controlled patients with type 2 diabetes mellitus: a placebo-controlled, double-blinded, randomized trial". Diabetes Technol. Ther. 8 (6): 636–43. doi:10.1089/dia.2006.8.636. PMID 17109595.
- Iqbal N, Cardillo S, Volger S et al. (January 2009). "Chromium Picolinate Does Not Improve Key Features of Metabolic Syndrome in Obese Nondiabetic Adults". Metab Syndr Relat Disord 7 (2): 143–50. doi:10.1089/met.2008.0048. PMC 3135886. PMID 19196082.
- Balk EM, Tatsioni A, Lichtenstein AH, Lau J, Pittas AG (2007). "Effect of chromium supplementation on glucose metabolism and lipids: a systematic review of randomized controlled trials". Diabetes Care 30 (8): 2154–2163. doi:10.2337/dc06-0996. PMID 17519436.
- Suksomboon, N.; Poolsup, N.; Yuwanakom, A. (2014). "Systematic review and meta-analysis of the efficacy and safety of chromium supplementation in diabetes". Journal of Clinical Pharmacy and Therapeutics (John Wiley & Sons) 39 (3): 292–306. doi:10.1111/jcpt.12147. Retrieved 30 March 2015.
- Anderson, Richard; Cheng, Nanzheng; Bryden, Noella; Polansky, Marilyn; Cheng, Nanping; Chi, Jiaming; Feng, Jinguang (1997). "Elevated Intakes of Supplemental Chromium Improve Glucose and Insulin Variables in Individuals With Type 2 Diabetes". Diabetes Care (American Diabetes Association) 46 (11): 1786–1791. doi:10.2337/diab.46.11.1786. Retrieved 30 March 2015.
- Broadhurst CL, Domenico P (December 2006). "Clinical studies on chromium picolinate supplementation in diabetes mellitus--a review". Diabetes Technol. Ther. 8 (6): 677–87. doi:10.1089/dia.2006.8.677. PMID 17109600.
- Trumbo PR, Ellwood KC (August 2006). "Chromium picolinate intake and risk of type 2 diabetes: an evidence-based review by the United States Food and Drug Administration". Nutr. Rev. 64 (8): 357–63. doi:10.1111/j.1753-4887.2006.tb00220.x. PMID 16958312.
- Dey, Lucy; Attele, Anoja (2002). "Alternative Therapies for Type 2 Diabetes". Alternative Medicine Review 7 (1): 45–58. Retrieved 30 March 2015.
- Hirst, Jennifer; Farmer, Andrew; Ali, Raghib; Roberts, Nia; Stevens, Richard (2012). "Quantifying the Effect of Metformin Treatment and Dose on Glycemic Control". Diabetes Care (American Diabetes Association) 35 (2): 446–454. doi:10.2337/dc11-1465. Retrieved 30 March 2015.
- Chaudhary S, Pinkston J, Rabile MM, Van Horn JD (2005). "Unusual reactivity in a commercial chromium supplement compared to baseline DNA cleavage with synthetic chromium complexes". Journal of Inorganic Biochemistry 99 (3): 787–794. doi:10.1016/j.jinorgbio.2004.12.009. PMID 15708800.
- Hininger I, Benaraba R, Osman M, Faure H, Marie Roussel A, Anderson RA (2007). "Safety of trivalent chromium complexes: no evidence for DNA damage in human HaCaT keratinocytes". Free Radic. Biol. Med. 42 (12): 1759–65. doi:10.1016/j.freeradbiomed.2007.02.034. PMID 17512455.
- Stallings DM, Hepburn DD, Hannah M, Vincent JB, O'Donnell J (2006). "Nutritional supplement chromium picolinate generates chromosomal aberrations and impedes progeny development in Drosophila melanogaster". Mutat. Res. 610 (1–2): 101–13. doi:10.1016/j.mrgentox.2006.06.019. PMID 16887379.
- Hepburn DD, Xiao J, Bindom S, Vincent JB, O'Donnell J (2003). "Nutritional supplement chromium picolinate causes sterility and lethal mutations in Drosophila melanogaster". Proc. Natl. Acad. Sci. U.S.A. 100 (7): 3766–71. doi:10.1073/pnas.0636646100. PMC 152996. PMID 12649323.
- Connett, Paul; Wetterhahn, Karen (1983). "Metabolism of the carcinogen chromate by cellular constituents". In Connett, Paul; Follmann, H; Lammers, M.; Mann, S.; Odom, J.; Wetterhahn, K. Inorganic Elements in Biochemistry. Berlin, Germany: Springer Berlin Heidelberg. pp. 93–124. ISBN 978-3-540-44420-6. Retrieved 20 March 2015.
- Stearns, Diane; Wise, John; Patierno, Steven; Wetterhahn, Karen (1995). "Chromium(III) picolinate produces chromosome damage in Chinese hamster ovary cells". FASEB journal (Federation of American Societies for Experimental Biology) 9 (15): 1643–1648. Retrieved 20 March 2015.
- Slesinski, Ronald; Clarke, Jane; San, Richard; Gudi, Ramadevi (2005). "Lack of mutagenicity of chromium picolinate in the hypoxanthine phosphoribosyltransferase gene mutation assay in Chinese hamster ovary cells". Mutation Research/Genetic Toxicology and Environmental Mutagenesis (Elsevier B.V) 585 (1-2): 86–95. Retrieved 30 March 2015.
- Kato, Ikuko; Vogelman, Joseph; Dilman, Vladimir; Karkoszka, Jerzy; Frenkel, Krystyna; Durr, Nancy; Orentreich, Norman; Toniolo, Paolo (1998). "Effect of supplementation with chromium picolinate on antibody titers to 5—hydroxymethyl uracil". European Journal of Epidemiology (Kluwer Academic Publishers) 14 (6): 621–626. doi:10.1023/A:1007442203258. Retrieved 20 March 2015.
- Tsou, Tsui—Chun; Chen, Chiu—lan; Liu, Tsung—Yun; Yang, Jia-Ling (1996). "Induction of 8-hydroxydeoxyguanosine in DNA by chromium(III) plus hydrogen peroxide and its prevention by scavengers". Carcinogenesis (Oxford University Press) 17 (1): 103–108. Retrieved 20 March 2015.
- Ozawa, T.; Hanaki, A. (1990). "Spin-trapping studies on the reactions of Cr(III) with hydrogen peroxide in the presence of biological reductants: is Cr(III) non-toxic?". Biochemistry International 22 (2): 343–352. Retrieved 20 March 2015.
- Jeejeebhoy, Khursheed (2009). "The Role of Chromium in Nutrition and Therapeutics and As a Potential Toxin". Nutrition Reviews (John Wiley & Sons) 57 (11): 329–335. doi:10.1111/j.1753-4887.1999.tb06909.x. Retrieved 20 March 2015.
- Fairhurst, S.; Minty, C. (1989). The toxicity of chromium and inorganic chromium compounds. Toxicity Review; 21. London: H.M.S.O. pp. 1–243. ISBN 9780118855211.
- Wasser, Walter; Feldman, Nathaniel; D'Agati, Vivette (1997). "Chronic Renal Failure after Ingestion of Over-the-Counter Chromium Picolinate". Annals of Internal Medicine (American College of Physicians) 126 (5): 410. doi:10.7326/0003-4819-126-5-199703010-00019. Retrieved 20 March 2015.
- Safe Upper Levels for Vitamins and Minerals Food Standards Agency - May 2003
- Risk assessment: Chromium Expert Group on Vitamins and Minerals, 2003
- STATEMENT ON THE MUTAGENICITY OF TRIVALENT CHROMIUM AND CHROMIUM PICOLINATE COM/04/S3 - December 2004
- Agency revises chromium picolinate advice Food Standards Agency - 13 December 2004
- "Monograph: Chromium (from Chromium picolinate)". Health Canada. December 9, 2009. Retrieved March 24, 2015.